Table 2 Efficacy outcomes
|  | CRC | Non-CRC | Overall study population (N = 103) | ||||
|---|---|---|---|---|---|---|---|
|  |  ≥ 2 Prior therapies (N = 41) | 1 Prior therapy (N = 24) | Total (N = 65) | GC (N = 18) | Other solid tumors (N = 20) | Total (N = 38) | |
BIRC | Â | Â | Â | Â | Â | Â | Â |
ORR | Â | Â | Â | Â | Â | Â | Â |
n (%) | 13 (31.7) | 15 (62.5) | 28 (43.1) | 8 (44.4) | 8 (40.0) | 16 (42.1) | 44 (42.7) |
95% CI | 18.1–48.1 | 40.6–81.2 | 30.8–56.0 | 21.5–69.2 | 19.1–63.9 | 26.3–59.2 | 33.0–52.8 |
DCR | Â | Â | Â | Â | Â | Â | Â |
n (%) | 24 (58.5) | 16 (66.7) | 40 (61.5) | 15 (83.3) | 13 (65.0) | 28 (73.7) | 68 (66.0) |
95% CI | 42.1–73.7 | 44.7–84.4 | 48.6–73.3 | 58.6–96.4 | 40.8–84.6 | 56.9–86.6 | 56.0–75.1 |
DoR | Â | Â | Â | Â | Â | Â | Â |
Range, months | 1.05 + to 16.59 +  | 2.76 + to 14.98 +  | 1.87 to 14.98 +  | 1.05 + to 16.59 +  | 3.75 + to 14.72 +  | 1.05 + to 16.59 +  | 1.05 + to 16.59 +  |
 ≥ 12 months, % (95% CI) | 74.6 (39.8–91.1) | 100.0 (100.0–100.0) | 88.4 (68.0–96.1) | 100.0 (100.0–100.0) | 100.0 (100.0–100.0) | 100.0 (100.0–100.0) | 92.2 (77.5–97.4) |
PFS | Â | Â | Â | Â | Â | Â | Â |
Median (95% CI), months | 4.9 (1.9–9.9) | NR (1.8–NE) | 7.2 (3.5–NE) | NR (11.1–NE) | NR (1.9–NE) | NR (5.5–NE) | 11.1 (5.5–NE) |
Range, months | 0.85 to 16.76 +  | 0.76 to 18.27 +  | 0.76 to 18.27 +  | 1.41 to 18.43 +  | 0.03 + to 16.62 +  | 0.03 + to 18.43 +  | 0.03 + to 18.43 +  |
% at 12 months (95% CI) | 32.1 (18.1–47.0) | 62.5 (40.3–78.4) | 43.7 (31.2–55.4) | 58.0 (18.3–84.0) | 52.6 (28.7–71.9) | 57.7 (37.3–73.5) | 48.5 (37.8–58.3) |
OS | Â | Â | Â | Â | Â | Â | Â |
Median (95% CI), months | NR (10.3–NE) | NR (NE–NE) | NR (NE–NE) | NR (NE–NE) | NR (5.9–NE) | NR (NE–NE) | NR (NE–NE) |
% at 12 months (95% CI) | 64.7 (47.7–77.4) | 87.1 (65.2–95.7) | 72.9 (60.1–82.2) | 83.3 (56.8–94.3) | 75.0 (50.0–88.7) | 78.9 (62.1–88.8) | 74.6 (64.7–82.1) |